HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Graham, M. M. Articles by Krohn, K. A. Search for Related Content PubMed PubMed Citation Articles by Graham, M. M. Articles by Krohn, K. A.

Fluorine-18-Fluoromisonidazole Radiation Dosimetry in Imaging Studies

Departments of Radiology and Radiation Oncology, University of Washington School of Medicine
Division of Cardiology, Department of Medicine, Seattle Veteran's Administration Medical Center, Seattle, Washington

Correspondence: For correspondence or reprints contact: Michael M. Graham, PhD, MD, Department of Radiology (Nuclear Medicine), Box 356113, University of Washington, Seattle, WA 98195.

ABSTRACT

Fluoromisonidazole (FMISO), labeled with the positron emitter ¹⁸F, is a useful hypoxia imaging agent for PET studies, with potential applications in patients with tumors, cardiovascular disease and stroke. Methods: Radiation doses were calculated in patients undergoing imaging studies to help define the radiation risk of FMISO-PET imaging. Time-dependent concentrations of radioactivity were determined in blood samples and PET images of patients following intravenous injection of [¹⁸F]FMISO. Radiation absorbed doses were calculated using the procedures of the Medical Internal Radiation Dose (MIRD) committee, taking into account the variation in dose based on the distribution of activities observed in the individual patients. As part of this study we also calculated an S value for brain to eye. Effective dose equivalent was calculated using ICRP 60 weights. Results: Effective dose equivalent was 0.013 mSv/MBq in men and 0.014 mSv/MBq in women. Individual organ doses for women were not different from men. Assuming bladder voiding at 2-or 4-hr intervals, the critical organ that received the highest dose was the urinary bladder wall (0.021 mGy/MBq with 2-hr voiding intervals or 0.029 mGy/MBq with 4-hr voiding intervals). Conclusion: The organ doses for [¹⁸F]FMISO are comparable to those associated with other commonly performed nuclear medicine tests and indicate that potential radiation risks associated with this study are within generally accepted limits.

Key Words: fluorine-18-fluoromisonidazole • dosimetry • Monte Carlo simulations

This article has been cited by other articles:

				K. A. Krohn, J. M. Link, and R. P. Mason Molecular Imaging of Hypoxia J. Nucl. Med., June 1, 2008; 49(Suppl_2): 129S - 148S. [Abstract] [Full Text] [PDF]

				J. R. Virta, T. Tolvanen, K. Nagren, A. Bruck, A. Roivainen, and J. O. Rinne 1-11C-Methyl-4-Piperidinyl-N-Butyrate Radiation Dosimetry in Humans by Dynamic Organ-Specific Evaluation J. Nucl. Med., March 1, 2008; 49(3): 347 - 353. [Abstract] [Full Text] [PDF]

				K. A. Krohn and J. G. Rajendran Hypoxia Imaging ASCO Educational Book, January 1, 2008; 2008(1): 538 - 541. [Abstract] [Full Text] [PDF]

				N. M. Scheinin, T. K. Tolvanen, I. A. Wilson, E. M. Arponen, K. A. Nagren, and J. O. Rinne Biodistribution and Radiation Dosimetry of the Amyloid Imaging Agent 11C-PIB in Humans J. Nucl. Med., January 1, 2007; 48(1): 128 - 133. [Abstract] [Full Text] [PDF]

				M. H. Cherk, S. S. Foo, A. M.T. Poon, S. R. Knight, C. Murone, A. T. Papenfuss, J. I. Sachinidis, T. H.C. Saunder, G. J. O'Keefe, and A. M. Scott Lack of Correlation of Hypoxic Cell Fraction and Angiogenesis with Glucose Metabolic Rate in Non-Small Cell Lung Cancer Assessed by 18F-Fluoromisonidazole and 18F-FDG PET J. Nucl. Med., December 1, 2006; 47(12): 1921 - 1926. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, K. A. Krohn, S. M. Larson, R. Weissleder, D. A. Mankoff, J. M. Hoffman, J. M. Link, K. Z. Guyton, W. C. Eckelman, H. I. Scher, et al. The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development Clin. Cancer Res., November 15, 2005; 11(22): 7967 - 7985. [Abstract] [Full Text] [PDF]

				H. Vesselle, J. Grierson, L. M. Peterson, M. Muzi, D. A. Mankoff, and K. A. Krohn 18F-Fluorothymidine Radiation Dosimetry in Human PET Imaging Studies J. Nucl. Med., September 1, 2003; 44(9): 1482 - 1488. [Abstract] [Full Text] [PDF]

				T. Tolvanen, K. Lehtio, J. Kulmala, V. Oikonen, O. Eskola, J. Bergman, and H. Minn 18F-Fluoroerythronitroimidazole Radiation Dosimetry in Cancer Studies J. Nucl. Med., December 1, 2002; 43(12): 1674 - 1680. [Abstract] [Full Text] [PDF]

				D. A. Mankoff, L. M. Peterson, T. J. Tewson, J. M. Link, J. R. Gralow, M. M. Graham, and K. A. Krohn [18F]Fluoroestradiol Radiation Dosimetry in Human PET Studies J. Nucl. Med., April 1, 2001; 42(4): 679 - 684. [Abstract] [Full Text]